Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

quantum physics

- PMLiVE

Moderna’s COVID-19 vaccine produces immune response in early trial

Antibodies observed in all participants tested

- PMLiVE

Merck expands partnership with Zymeworks for multispecific antibodies

New licence agreement builds on existing collaboration

- PMLiVE

Moderna clashes with US scientists over pivotal COVID-19 vaccine trials

Delays allegedly resulting from a lack of cooperation

- PMLiVE

Pfizer eyes 20-strain Prevnar filing this year, after phase 3 win

New-generation shot could protect franchise from rival Merck & Co

- PMLiVE

First patients dosed with Moderna’s COVID-19 vaccine

More pharma players also join vaccine development efforts

AstraZeneca AZ

AZ’s comeback drug cediranib stumbles in phase 3 trial

Failed to improve on platinum-based chemotherapy

- PMLiVE

Keytruda hits primary endpoint in confirmatory lymphoma trial

Interim analysis demonstrates improvement in progression-free survival

- PMLiVE

Moderna and GSK advance coronavirus vaccine candidates

Developments come amid rapidly growing cases across the globe

- PMLiVE

Immutep spikes on trial of its LAG-3 drug with Keytruda

Impressive mid-stage results in NSCLC and HNSCC

- PMLiVE

Merck’s Ebola vaccine wins approval in four African countries

Follows approvals in US and Europe last year

- PMLiVE

Merck chases Roche with triple-negative breast cancer data for Keytruda

Data demonstrated a delay in disease progression or death

- PMLiVE

NICE turns down Keytruda/Inlyta combo for kidney cancer

Cost-effectiveness agency says the long-term benefit is uncertain

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links